Sivori Martin L, Raimondi Guillermo A
Unidad de Neumotisiología, Hospital Ramos Mejía, Buenos Aires.
Medicina (B Aires). 2004;64(2):113-9.
A survey on COPD diagnostic procedures, treatment and management was conducted in a group of 517 chest physicians randomized from a list of the 1121 affiliates to the Asociación Argentina de Medicina Respiratoria. One hundred eighty-seven responses were obtained (36.2% of the questionnaires mailed). They treat an average of 53.3 COPD patients every month. Twenty-four percent of them had mild, 41.8% moderate and 33.8% severe disease (GOLD criteria). Only clinical criteria for diagnosis of COPD, clinical criteria + spirometry (S), and clinical criteria + S + chest X ray were used by 2.9, 23.4 and 73.7% of responders, respectively. Seventy percent of responders believed that chronic asthma without bronchodilator response must be included in the COPD definition. Only 14.1% of responders performed S in every office visit. Cardiac function was assessed using clinical criteria, electrocardiogram and echocardiogram by 90.6, 80.6 and 73.8% of responders, respectively, while 98.3% stated that they trained most of their patients in the inhalation technique. Metered Dose Inhaled was the first option for bronchodilators administration (64.8%) followed by nebulization (16.5%), dry powder inhalation (13.7%) and oral administration (4.8%). First option for chronic therapy in severe COPD patients was the association of anticholinergic drug (AC) + short acting beta2-agonists (SABA) (65.5%), AC alone (18.8%), long acting beta2-agonists (LABA) (9.7%), inhaled corticosteroids (IC) (3.5%) and SABA alone (2.8%). Corticosteroids and antibiotics were prescribed in severe COPD exacerbation by 92.5 and 70% of responders, respectively. First choice antibiotic formulation was beta-lactamics + beta-lactamase inhibitors in 39% of the responders followed by fluorquinolones in 23.7%, macrolides in 17.5% and beta-lactamics in 12.5%. Lastly, 12.7% of COPD patients received long-term domiciliary oxygen therapy. 59.3% of them were prescribed pulmonary rehabilitation, 94.1% vaccination against influenza and 91.4% pneumococcal vaccination. Thirty seven percent of the patients continued to smoke. Most of reponses regarding diagnosis and exacerbation treatment were in agreement with recommendations of international guidelines. For maintenance treatment the association of AC + SABA was commonly recommended as first option, whereas IC and LABA were rarely prescribed.
对从阿根廷呼吸医学协会1121名会员名单中随机抽取的517名胸科医生进行了一项关于慢性阻塞性肺疾病(COPD)诊断程序、治疗与管理的调查。共获得187份回复(占邮寄问卷的36.2%)。他们每月平均治疗53.3名COPD患者。其中24%的患者患有轻度疾病,41.8%为中度,33.8%为重度疾病(采用慢性阻塞性肺疾病全球倡议(GOLD)标准)。分别有2.9%、23.4%和73.7%的受访者仅使用COPD临床诊断标准、临床标准 + 肺功能测定(S)以及临床标准 + S + 胸部X线检查。70%的受访者认为慢性哮喘且无支气管扩张剂反应的情况应纳入COPD的定义中。仅14.1%的受访者在每次门诊时都进行肺功能测定。分别有90.6%、80.6%和73.8%的受访者使用临床标准、心电图和超声心动图来评估心功能,而98.3%的受访者表示他们对大多数患者进行了吸入技术培训。定量吸入器是支气管扩张剂给药的首选方式(64.8%),其次是雾化吸入(16.5%)、干粉吸入(13.7%)和口服给药(4.8%)。重度COPD患者慢性治疗的首选是抗胆碱能药物(AC) + 短效β2受体激动剂(SABA)联合使用(65.5%),单独使用AC(18.8%),长效β2受体激动剂(LABA)(9.7%),吸入性糖皮质激素(IC)(3.5%)以及单独使用SABA(2.8%)。分别有92.5%和70%的受访者在重度COPD急性加重期使用糖皮质激素和抗生素。39%的受访者首选的抗生素制剂是β - 内酰胺类 + β - 内酰胺酶抑制剂,其次是氟喹诺酮类(23.7%)、大环内酯类(17.5%)和β - 内酰胺类(12.5%)。最后,12.7% 的COPD患者接受了长期家庭氧疗。59.3%的患者接受了肺康复治疗,94.1%的患者接种了流感疫苗,91.4%的患者接种了肺炎球菌疫苗。37%的患者继续吸烟。关于诊断和急性加重期治疗的大多数回复与国际指南的建议一致。对于维持治疗,AC + SABA联合使用通常被推荐为首选方案,而IC和LABA很少被处方。